RU95112537A - THERAPEUTIC HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING - Google Patents

THERAPEUTIC HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING

Info

Publication number
RU95112537A
RU95112537A RU95112537/04A RU95112537A RU95112537A RU 95112537 A RU95112537 A RU 95112537A RU 95112537/04 A RU95112537/04 A RU 95112537/04A RU 95112537 A RU95112537 A RU 95112537A RU 95112537 A RU95112537 A RU 95112537A
Authority
RU
Russia
Prior art keywords
formula
compound
group
physiologically
solvate
Prior art date
Application number
RU95112537/04A
Other languages
Russian (ru)
Other versions
RU2160736C2 (en
Inventor
Дункан Робертсон Алан
Питер Хилл Алан
Чарльз Глен Роберт
Ричард Мартин Грэм
Original Assignee
Дзе Веллкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909012672A external-priority patent/GB9012672D0/en
Priority claimed from GB919102182A external-priority patent/GB9102182D0/en
Application filed by Дзе Веллкам Фаундейшн Лимитед filed Critical Дзе Веллкам Фаундейшн Лимитед
Publication of RU95112537A publication Critical patent/RU95112537A/en
Application granted granted Critical
Publication of RU2160736C2 publication Critical patent/RU2160736C2/en

Links

Claims (14)

1. Соединение формулы (I)
Figure 00000001

в которой n является целым числом от 0 до 3, W является группой формулы (i), (ii) или (iii)
Figure 00000002

в которой R является водородом или С1-C4-алкилом, Х является -О-, -S-, -NН- или -СН2-, Y является кислородом или серой, а хиральный центр* в формуле (i) или (ii) находится в своей (S)- или (R)-форме или является смесью их в любых соотношениях; Z является группой формулы (iv), (v) или (vi)
Figure 00000003

в которой R1 и R2 независимо выбираются из водорода и С1-C4- алкила, а R3 является водородом или С1-C4-алкилом, и соли, сольваты и физиологически функциональные производные его при условии, что исключается соединение: N, N-диметил-2-[5-(2-оксо-1,3-оксазолидин-4-ил-метил)-1Н-индол-3-ил]-этиламин.1. The compound of formula (I)
Figure 00000001

in which n is an integer from 0 to 3, W is a group of formula (i), (ii) or (iii)
Figure 00000002

in which R is hydrogen or C 1 -C 4 -alkyl, X is -O-, -S-, -NH- or -CH 2 -, Y is oxygen or sulfur, and a chiral center * in the formula (i) or ( ii) is in its (S) - or (R) -form or is a mixture of them in any ratios; Z is a group of formula (iv), (v) or (vi)
Figure 00000003

in which R 1 and R 2 are independently selected from hydrogen and C 1 -C 4 is alkyl, and R 3 is hydrogen or C 1 -C 4 -alkyl, and salts, solvates and physiologically functional derivatives thereof, provided that the compound is excluded: N, N-dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1H-indol-3-yl] -ethylamine. 2. Соединение формулы (I) по п. 1, отличающееся тем, что n является 1, или W является группой формулы (i), или Z является группой формулы (iv) или (vi), и физиологически приемлемые соли, сольваты и физиологически функциональные производные его. 2. The compound of formula (I) according to claim 1, characterized in that n is 1, or W is a group of formula (i), or Z is a group of formula (iv) or (vi), and physiologically acceptable salts, solvates and physiologically functional derivatives of it. 3. Соединение формулы (I) по п. 1, отличающееся тем, что n является 0, W является группой формулы (i), где R является водородом, Х является -O-, а Y является кислородом, и Z является группой формулы (iv) или (vi), где R1 = R2 - водород или метил, и физиологически приемлемые соли, сольваты и физиологически функциональные производные его.3. The compound of formula (I) according to claim 1, characterized in that n is 0, W is a group of formula (i), where R is hydrogen, X is -O-, and Y is oxygen, and Z is a group of formula ( iv) or (vi), where R 1 = R 2 is hydrogen or methyl, and physiologically acceptable salts, solvates and physiologically functional derivatives thereof. 4. Соединение формулы (I) по п. 1, отличающееся тем, что соединением является 3-(1-метил-4-пиперидил)-5-(2-оксо-1,3-оксазолидин-4-ил-метил)-1H-индол или в его (S)- или (R)-форме, или в виде смеси их в любых соотношениях, или физиологически приемлемой солью, сольватом или физиологически функциональным производным их. 4. The compound of formula (I) under item 1, characterized in that the compound is 3- (1-methyl-4-piperidyl) -5- (2-oxo-1,3-oxazolidin-4-yl-methyl) - 1H-indole or in its (S) - or (R) -form, or in the form of a mixture of them in any ratios, or a physiologically acceptable salt, solvate or physiologically functional derivative of them. 5. Соединение формулы (I) по любому из пп. 1 - 4, или физиологически приемлемая соль, сольват или физиологически функциональное производное его, для использования в качестве лекарственного средства. 5. The compound of formula (I) according to any one of paragraphs. 1 to 4, or a physiologically acceptable salt, solvate, or physiologically functional derivative thereof, for use as a medicine. 6. Соединение формулы (I) по любому из пп. 1 - 4, или физиологически приемлемая соль, сольват или физиологически функциональное производное его, для использования при профилактике или лечении клинического состояния, для которого показано применение агониста для "5-НТ1-подобного" рецептора.6. The compound of formula (I) according to any one of paragraphs. 1 to 4, or a physiologically acceptable salt, solvate, or physiologically functional derivative thereof, for use in the prophylaxis or treatment of a clinical condition for which the use of an agonist for the “5-HT 1 -like” receptor is indicated. 7. Соединение формулы (I) по любому из пп. 1 - 4 или физиологически приемлемая соль, сольват или физиологически функциональное производное его, для использования при профилактике или лечении мигрени. 7. The compound of formula (I) according to any one of paragraphs. 1 to 4 or a physiologically acceptable salt, solvate or physiologically functional derivative thereof, for use in the prevention or treatment of migraine. 8. Соединение формулы (I) по любому из пп. 1 - 4, или физиологически приемлемая соль, сольват или физиологически функциональное производное его, используемое при изготовлении лекарственного средства для профилактики или лечения клинического состояния, для которого показан агонист для "5-НТ1-подобного" рецептора.8. The compound of formula (I) according to any one of paragraphs. 1 to 4, or a physiologically acceptable salt, solvate, or physiologically functional derivative thereof, used in the manufacture of a medicament for the prevention or treatment of a clinical condition for which an agonist is indicated for a "5-HT 1 -like" receptor. 9. Соединение формулы (I) по любому из пп. 1 - 4, или физиологически приемлемая соль, сольват или физиологически функциональное производное его, используемое при изготовлении лекарственного средства для профилактики или лечения мигрени. 9. The compound of formula (I) according to any one of paragraphs. 1 to 4, or a physiologically acceptable salt, solvate, or physiologically functional derivative thereof, used in the manufacture of a medicament for the prevention or treatment of migraine. 10. Лекарственное средство, отличающееся тем, что в качестве активного компонента включает эффективное количество соединения формулы (I) по любому из пп. 1 - 4, или физиологически приемлемую соль, сольват или физиологически функциональное производное его, фармацевтически приемлемый носитель и, необязательно, одно или более других физиологически активных средств. 10. Drug, characterized in that as the active component includes an effective amount of the compounds of formula (I) according to any one of paragraphs. 1 to 4, or a physiologically acceptable salt, solvate, or physiologically functional derivative thereof, a pharmaceutically acceptable carrier, and, optionally, one or more other physiologically active agents. 11. Средство по п. 10 в форме таблетки или капсулы. 11. Means under item 10 in the form of a tablet or capsule. 12. Способ получения соединения формулы (I)
Figure 00000004

в которой n является целым числом от 0 до 3, W является группой формулы (i), (ii) или (iii)
Figure 00000005

где R является водородом или С1-С4-алкилом, Х является -О-, -S-, -NН- или -CH2-, Y является кислородом или серой, а хиральный центр * в формуле (i) или (ii) находится в его (S)- или (R)-форме или является смесью их в любых соотношениях; и Z является группой формулы (iv), (v) или (vi)
Figure 00000006

где R1 и R2 независимо выбираются из водорода и С1-C4-алкила, а R3 является водородом или С1-C4-алкилом, при условии, что исключается соединение N, N-диметил-2-[5-(2-оксо-1,3-оксазолидин-4-ил-метил)-1Н-индол-3-ил] -этиламин, отличающийся тем, что (а) в случае, когда Z является группой формулы (iv), осуществляют реакцию соединения формулы (II)
Figure 00000007

где n и W имеют определенные выше значения, с соединением формулы (III)
Figure 00000008
или с карбонил-защищенной формой его, где L является подходящей удаляемой группой или защищенной аминогруппой, которая может быть превращена in situ в аминогруппу или является группой -NR1R2, где R1 и R2 имеют определенные выше значения; (б) в случае, когда Z является группой формулы (V), проводят реакцию соединения формулы (XXXI)
Figure 00000009

где n и W имеют определенные выше значения,
с соединением формулы (ХХУIII)
Figure 00000010

где R3 имеет определенные выше значения, и (в) в случае, когда Z является группой формулы (vi), восстанавливают соединение формулы (I), в которой n и W имеют определенные выше значения, а Z является группой формулы (V), или в случае, когда Y является группой формулы (i) или (ii), проводят реакцию соединения формулы (ХУ)
Figure 00000011

или (ХХУ)
Figure 00000012

где n, R и Х имеют определенные выше значения, а Z является группой формулы (vi),
с соединением формулы (У11)
Figure 00000013

где Y имеет определенные выше значения, а L и L1, которые могут быть одинаковыми или различными, являются подходящими уходящими группами, и необязательно превращают соединение формулы (I), полученное таким образом, в соответствующую соль, сольват или физиологически функциональное производное его.12. The method of obtaining the compounds of formula (I)
Figure 00000004

in which n is an integer from 0 to 3, W is a group of formula (i), (ii) or (iii)
Figure 00000005

where R is hydrogen or C 1 -C 4 -alkyl, X is -O-, -S-, -NH- or -CH 2 -, Y is oxygen or sulfur, and the chiral center * in the formula (i) or (ii ) is in its (S) - or (R) -form or is a mixture of them in any ratios; and Z is a group of formula (iv), (v) or (vi)
Figure 00000006

where R 1 and R 2 are independently selected from hydrogen and C 1 -C 4 -alkyl, and R 3 is hydrogen or C 1 -C 4 -alkyl, provided that the compound N, N-dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-yl-methyl) -1H-indol-3-yl] -ethylamine, characterized in that (a) when Z is a group of formula (iv), the reaction is carried out compounds of formula (II)
Figure 00000007

where n and W are as defined above, with a compound of formula (III)
Figure 00000008
or with a carbonyl protected form thereof, where L is a suitable leaving group or a protected amino group that can be converted in situ to an amino group or is —NR 1 R 2 , where R 1 and R 2 are as defined above; (b) in the case when Z is a group of formula (V), the compounds of formula (XXXI) are reacted
Figure 00000009

where n and W are as defined above,
with the compound of the formula (XXYIII)
Figure 00000010

wherein R 3 is as defined above, and (c) in the case where Z is a group of formula (vi), the compound of formula (I) is reduced, in which n and W are as defined above, and Z is a group of formula (V), or in the case when Y is a group of formula (i) or (ii), the compounds of formula (XU) are reacted
Figure 00000011

or (xxx)
Figure 00000012

where n, R and X are as defined above, and Z is a group of formula (vi),
with the compound of the formula (Y11)
Figure 00000013

where Y is as defined above, and L and L 1 , which may be the same or different, are suitable leaving groups, and optionally convert the compound of formula (I), thus obtained, to the corresponding salt, solvate or physiologically functional derivative thereof. 13. Способ получения лекарственного средства, отличающийся тем, что (а) получают соединение формулы (I) или его физиологически приемлемую соль, сольват или физиологически функциональное производное его по способу, заявленному в п. 12, и (б) смешивают продукт реакции из стадии (а) с фармацевтически приемлемым носителем и необязательно одним или более другими физиологически активными средствами. 13. The method of obtaining a medicinal product, characterized in that (a) receive a compound of formula (I) or its physiologically acceptable salt, solvate or physiologically functional derivative of it according to the method stated in paragraph 12, and (b) mix the reaction product from stage (a) with a pharmaceutically acceptable carrier and optionally one or more other physiologically active agents. 14. Способ по п. 13, отличающийся тем, что включает дополнительную стадию (в), в которой смеси из стадии (б) придают форму таблетки или капсулы. 14. The method according to p. 13, characterized in that it includes an additional stage (c), in which the mixture from stage (b) is shaped into a tablet or capsule.
RU95112537/04A 1990-06-07 1991-06-06 Indole derivatives and physiologically acceptable salts and solvates thereof, methods of preparing thereof, drug for treatment or prophylaxes of clinical states for which administration of 5-ht1-like receptor agonist, and method of preparing thereof RU2160736C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909012672A GB9012672D0 (en) 1990-06-07 1990-06-07 Therapeutic heterocyclic compounds
GB9012672.3 1990-06-07
GB9102182.4 1991-02-01
GB919102182A GB9102182D0 (en) 1991-02-01 1991-02-01 Therapeutic heterocyclic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU501147304 Addition 1992-02-06

Publications (2)

Publication Number Publication Date
RU95112537A true RU95112537A (en) 1997-08-10
RU2160736C2 RU2160736C2 (en) 2000-12-20

Family

ID=26297174

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95112537/04A RU2160736C2 (en) 1990-06-07 1991-06-06 Indole derivatives and physiologically acceptable salts and solvates thereof, methods of preparing thereof, drug for treatment or prophylaxes of clinical states for which administration of 5-ht1-like receptor agonist, and method of preparing thereof

Country Status (37)

Country Link
US (3) US5399574A (en)
EP (2) EP0636623B1 (en)
JP (1) JP2738461B2 (en)
KR (1) KR100215627B1 (en)
AT (2) ATE156823T1 (en)
AU (1) AU646871B2 (en)
CA (2) CA2282890C (en)
CZ (1) CZ288351B6 (en)
DE (3) DE69127260T2 (en)
DK (1) DK0486666T3 (en)
EG (1) EG19650A (en)
ES (1) ES2104708T3 (en)
FI (3) FI105686B (en)
GR (1) GR3024828T3 (en)
HK (1) HK1000534A1 (en)
HR (1) HRP940524B1 (en)
HU (2) HU219974B (en)
IE (1) IE911931A1 (en)
IL (3) IL98392A (en)
LT (1) LT3264B (en)
LU (1) LU90205I2 (en)
LV (1) LV10274B (en)
MC (1) MC2210A1 (en)
MX (1) MX9203421A (en)
MY (1) MY110226A (en)
NL (1) NL980001I2 (en)
NO (2) NO300634B1 (en)
NZ (1) NZ238424A (en)
PL (1) PL166214B1 (en)
PT (1) PT97888B (en)
RU (1) RU2160736C2 (en)
SA (1) SA05260104B1 (en)
SI (2) SI21560B (en)
SK (1) SK281621B6 (en)
UA (1) UA37178C2 (en)
WO (1) WO1991018897A1 (en)
YU (1) YU48855B (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283018B6 (en) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives, process of their preparation, their use and pharmaceuticals based thereon
TW263508B (en) * 1991-02-12 1995-11-21 Pfizer
ES2143992T3 (en) * 1991-11-25 2000-06-01 Pfizer DERIVATIVES OF 5- (HETERO- OR CARBOCICLILAMINO) -INDOL, ITS PREPARATION AND USE AS 5-HT1 AGONISTS.
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (en) * 1992-03-05 1996-10-11 Pfizer
JP3309982B2 (en) * 1992-03-13 2002-07-29 メルク シヤープ エンド ドーム リミテツド Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
UA27467C2 (en) 1992-04-07 2000-09-15 Пфайзер Інк. Indole derivatives as 5-ht1 agonists and intermediates
AU670270B2 (en) * 1992-04-10 1996-07-11 Pfizer Inc. Acylaminoindole derivatives as 5-HT1 agonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
JPH07509452A (en) * 1992-07-24 1995-10-19 メルク　シヤープ　エンド　ドーム　リミテツド Imidazole, triazole and tetrazole derivatives
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme 4-substituted 1, 2, 4-triazole derivatives, their preparation and pharmaceutical compositions containing them
ES2056025B1 (en) * 1992-10-08 1995-05-01 Almirall Lab NEW DERIVATIVES OF INDOL.
TW251284B (en) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (en) * 1993-02-02 1995-03-31 Adir New derivatives of indole, indazole and benzisoxazole, process for their preparation and pharmaceutical compositions containing them.
ES2070087B1 (en) * 1993-08-13 1996-02-16 Pfizer DERIVATIVES OF INDOL
US5849739A (en) * 1993-08-31 1998-12-15 Pfizer Inc. 5-arylindole derivatives
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
ES2161892T3 (en) * 1994-06-01 2001-12-16 Astrazeneca Ab DERIVATIVES OF INDOL AS PROPHARMACES OF AGONISTS OF THE RECEIVERS RELATED TO 5-HT1.
MX9700693A (en) * 1994-07-26 1997-04-30 Pfizer 4-indole derivatives as serotonin agonists and antagonists.
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
JPH10509721A (en) * 1994-12-06 1998-09-22 メルク シヤープ エンド ドーム リミテツド Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
DE4443892A1 (en) * 1994-12-09 1996-06-13 Bayer Ag 4- (Quinolin-2-yl-methoxy) phenyl acetic acid derivatives
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
JPH11502816A (en) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー 5-Substituted-3- (1,2,3,6-tetrahydropyridin-4-yl)-and 3- (piperidin-4-yl) -1H-indoles: new 5-HT (1F) agonists
GB9515060D0 (en) * 1995-07-22 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9515305D0 (en) * 1995-07-26 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9516143D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6909005B1 (en) * 1995-08-07 2005-06-21 Astrazeneca Uk Limited One post synthesis of 2-oxazolidinone derivatives
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
WO1997016446A1 (en) * 1995-11-02 1997-05-09 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AR017200A1 (en) 1997-12-23 2001-08-22 Astrazeneca Ab INHIBITING COMPOUNDS OF PROTEIN CINASE C, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THEM, USE THE SAME AND PROCESS FOR THE SYNTHESIS OF SUCH COMPOUNDS
SE9800835D0 (en) 1998-03-13 1998-03-13 Astra Ab New Compounds
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
JP2004517081A (en) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー 1- (2-m-methanesulfonamidophenylethyl) -4- (m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvates thereof
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
CN100378108C (en) 2002-06-21 2008-04-02 苏文生命科学有限公司 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
DE60329607D1 (en) 2002-06-21 2009-11-19 Suven Life Sciences Ltd CONTAINING THERAPEUTIC AGENT ARYL ALKYLINDOLE WITH AFFINITY FOR THE SEROTONIN RECEPTOR, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
ES2204302B2 (en) * 2002-08-07 2005-03-01 Laboratorios Vita, S.A. PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND.
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004048328A2 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
EP1581538B1 (en) 2002-12-18 2007-02-28 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
CA2508290C (en) 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
WO2004063175A1 (en) * 2003-01-13 2004-07-29 Natco Pharma Limited A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20040192958A1 (en) * 2003-03-25 2004-09-30 Hyatt John Anthony Process for preparing derivatives of 4-halobutyraldehyde
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
AR044688A1 (en) * 2003-06-12 2005-09-21 Euro Celtique Sa USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
UA84710C2 (en) * 2003-07-24 2008-11-25 Евро-Селтик С.А. Piperidine compounds, pharmaceutical compositions containing them and treatment method
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
JP5833804B2 (en) * 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Substituted indole compounds having NOS inhibitory activity
EP1981860B1 (en) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
CN101466709B (en) 2006-04-13 2013-03-20 轴突公司 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
AU2007310949A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
PL2425820T3 (en) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
CZ2007158A3 (en) * 2007-02-26 2008-10-22 Zentiva, A. S. Process for preparing zolmitriptan
ES2594867T3 (en) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
NZ579820A (en) * 2007-04-27 2011-01-28 Purdue Pharma Lp Therapeutic agents useful for treating pain
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
JP2010540613A (en) * 2007-10-03 2010-12-24 ジェネリクス・（ユーケー）・リミテッド Method for preparing zolmitriptan, a salt thereof, and a solvate thereof
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
BRPI0820632A2 (en) * 2007-11-16 2015-06-16 Neuraxon Inc Indole Compounds and Methods for Treating Visceral Pain
CN101181267B (en) * 2007-11-30 2010-09-08 重庆医科大学医药研究所 Zolmitriptan tongue tablet
KR101517415B1 (en) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20110038928A1 (en) * 2009-08-12 2011-02-17 Glenmark Generics Ltd Orally disintegrating tablets of zolmitriptan
PL2627328T3 (en) 2010-10-15 2017-03-31 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
RU2621708C2 (en) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Antagonists of trpv1, containing dihydroxy group as substitute, and their use
ES2751388T3 (en) 2011-07-22 2020-03-31 Univ Chicago IGF-1 for use in the treatment of migraine
WO2013057739A2 (en) * 2011-09-02 2013-04-25 Emcure Pharmaceuticals Limited An improved process for preparation of zolmitriptan
PL2838517T3 (en) 2012-04-18 2018-03-30 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
CN108697637A (en) 2016-01-27 2018-10-23 因斯塔尔科技股份公司 Oral mucosa nano fibre carrier for therapeutic treatment
CN109689036A (en) 2016-07-11 2019-04-26 康特拉医药公司 For treating morning akinetic pulse delivery system
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
KR20220024403A (en) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. Substituted pyrazolo-pyrazines and their use as GLUN2B receptor modulators
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB148879A (en) * 1919-02-14 1921-11-10 Emil Vincance Noser Locks for shift levers of automobiles
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US3879410A (en) * 1971-02-08 1975-04-22 Messrs Lab Guidotti & C S P A 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity
BE795457A (en) * 1972-02-16 1973-08-16 Clin Midy INDOLIC AMINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
FR2179582B1 (en) * 1972-04-13 1975-10-10 Synthelabo
US3873559A (en) * 1973-03-30 1975-03-25 Squibb & Sons Inc Heterocyclic carboxamido thiazolinyl indoles
US4042595A (en) * 1973-08-01 1977-08-16 Snam Progetti S.P.A. Processes for the production of heterocyclic compounds
IT995110B (en) * 1973-08-01 1975-11-10 Snam Progetti PROCEDURE FOR THE PRODUCTION OF HETEROCYCLIC COMPOUNDS AND OBTAINED PRODUCTS
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
FR2315925A1 (en) * 1975-07-04 1977-01-28 Nippon Chemiphar Co NEW 5-BENZYL-2-OXAZOLIDONE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
GB1482879A (en) * 1975-07-24 1977-08-17 Nippon Chemiphar Co 5-benzyl-2-oxazolidone derivatives and a process for producing the same
GB1469200A (en) * 1975-11-28 1977-03-30 Warner Lambert Co 3-thiomethyl-2-2-dialkylamino-ethyl-indoles
DE2557341A1 (en) * 1975-12-19 1977-06-30 Hoechst Ag BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
IT1109002B (en) * 1977-09-22 1985-12-16 Menarini Sas DERIVATIVES OF 2 OXAZOLIDONE AND THEIR PREPARATION METHODS
US4198501A (en) * 1977-12-20 1980-04-15 Hoffmann-La Roche Inc. Synthesis of tryptophans
US4137404A (en) * 1977-12-20 1979-01-30 Hoffmann-La Roche Inc. Synthesis of tryptophans
JPS6014032B2 (en) * 1978-01-20 1985-04-11 日本ケミフア株式会社東京 5-phenethyl-2-oxazolidone derivative and its production method
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2933636A1 (en) * 1978-08-30 1980-03-20 Sandoz Ag NEW N-PHENYLINDOL DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4272555A (en) * 1979-09-21 1981-06-09 Monsanto Company Conversion of carbon-containing materials to carbon monoxide
EP0038298B1 (en) * 1980-04-10 1984-07-25 Sandoz Ag Isoxazolyl indolamines
JPS574986A (en) * 1980-06-13 1982-01-11 Paamakemu Asia:Kk Preparation of oxazolidine derivative
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
DE3131728A1 (en) * 1980-08-12 1982-03-11 Glaxo Group Ltd., London INDOLDE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
BE889931A (en) * 1980-08-12 1982-02-11 Glaxo Group Ltd INDOLIC DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATIONS AS MEDICAMENTS
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4407811A (en) * 1981-01-02 1983-10-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4399296A (en) * 1981-01-02 1983-08-16 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4448971A (en) * 1981-01-02 1984-05-15 Pfizer Inc. Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones
JPS57169458A (en) * 1981-04-13 1982-10-19 Paamakemu Asia:Kk Preparation of indole derivative
CH656124A5 (en) * 1982-04-13 1986-06-13 Sandoz Ag 2-SUBSTITUTED-3-INDOLAMINES, METHOD FOR THE PRODUCTION AND USE THEREOF.
IT1170387B (en) * 1982-06-07 1987-06-03 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS, PROCEDURE TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4500717A (en) * 1983-03-28 1985-02-19 The Dow Chemical Company Process for preparation of 2-oxazolidinones
US4831153A (en) * 1983-06-27 1989-05-16 The Dow Chemical Company Preparation of N-vinyl-2-oxazolidinone
GB8321813D0 (en) * 1983-08-12 1983-09-14 Vickers Plc Radiation sensitive compounds
DE3333450A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt CARBONYL METHYLENE HETEROCYCLES CONTAINING TRIHALOGEN METHYL GROUPS, METHOD FOR THE PRODUCTION THEREOF AND LIGHT-SENSITIVE MIXTURE THAT CONTAINS THESE COMPOUNDS
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3430284A1 (en) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln NEW TRYPTAMINE DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND THEIR USE
IT1181741B (en) * 1984-12-04 1987-09-30 Glaxo Group Ltd INDOLATION DERIVATIVES, PROCEDURE TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3514696A1 (en) * 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-INDOLYLETHYL SULPHONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3531658A1 (en) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh HETEROCYCLICALLY SUBSTITUTED INDOLE, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
DE3678805D1 (en) * 1985-11-08 1991-05-23 Glaxo Group Ltd INDOLDER DERIVATIVES.
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
SE451840B (en) * 1986-01-03 1987-11-02 Astra Laekemedel Ab OPTICALLY PURE MONOHYDRATED OF S - (-) - 1-PROPYL-2 ', 6'-PIPECOLOXYLIDE HYDROCHLORIDE, SET TO PREPARE THIS AND PHARMACEUTICAL PREPARATIONS FOR LOCAL ANCHORING
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8607824D0 (en) * 1986-03-27 1986-04-30 Glaxo Group Ltd Chemical compounds
DE3643957A1 (en) * 1986-12-22 1988-06-30 Bayer Ag SUBSTITUTED N-METHYLISOXAZOLIDINE
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DK172696B1 (en) * 1987-08-13 1999-05-31 Glaxo Group Ltd Indole derivatives, processes for their preparation and pharmaceutical compositions containing the compounds
DE3730777A1 (en) * 1987-09-12 1989-03-23 Basf Ag METHOD FOR PRODUCING IMIDAZOLIDINONES AND OXAZOLIDINONES
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE3823299A1 (en) * 1988-07-07 1990-01-11 Schering Ag SUBSTITUTED PHENYL-PYRROLIDIN-2-ONE, -OXAZOLIDIN-2-ONE AND -IMIDAZOLIDIN-2-ONE, THEIR PRODUCTION AND USE IN MEDICINAL PRODUCTS
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
DE68918792T2 (en) * 1988-09-15 1995-03-30 Upjohn Co 5-indolinyl-5-beta-amidomethyloxazolidin-2-one, 3- (substituted condensed) phenyl-5-beta amidomethyloxazolidin-2-one and 3- (nitrogen-substituted) phenyl-5-beta-amidomethyloxazolidin-2-one.
DE3939238A1 (en) * 1989-11-28 1991-05-29 Bayer Ag HETEROCYCLICALLY SUBSTITUTED ACRYLIC ACID ESTERS
DE4013907A1 (en) * 1990-04-26 1991-10-31 Schering Ag Prepn. of 3-alkylamino methyl-indole derivs. from indole deriv.
CZ283018B6 (en) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives, process of their preparation, their use and pharmaceuticals based thereon
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives

Similar Documents

Publication Publication Date Title
RU95112537A (en) THERAPEUTIC HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING
SI21560B (en) 3,5-disubstituted indole derivatives as &#34;5-ht1-similar&#34; receptor agonist1
JP6926189B2 (en) Estrogen receptor regulator
RU2330661C2 (en) Combinations containing antidiarrheal agent and epothylon or epothylon derivatives
JP2020531434A (en) Solid form of HIV capsid inhibitor
RU2001121186A (en) Derivatives of pyrazolecarboxylic acid, their preparation, pharmaceutical compositions containing them
CA2498415C (en) Solid formulations comprising an indolinone compound
HUT50163A (en) Process for production of derivatives of indole and medical compositions containing them as active substance
RU2004104625A (en) ANALOGUES OF PROSTAGLANDINS AS EP4 RECEPTOR AGONISTS
CN103415289A (en) Pro-neurogenic compounds
JPS63198623A (en) Medicinal composition
RU2004122102A (en) NEW BENZIMIDAZOLE DERIVATIVES AND THEIR APPLICATION AS MEDICINES
TW200307535A (en) Therapeutic agent for cancer
JPWO2006088193A1 (en) Antitumor agent
KR890008155A (en) Novel derivatives, preparations thereof and use in medicine
JPH01160975A (en) 3-(4-(1-substituted-4-piperadinyl)butyl)-4-thiaz- olidinone and its production
WO2005018672A1 (en) Drug containing chymase inhibitor as the active ingredient
JPH0150700B2 (en)
TWI241293B (en) Pharmaceutical compositions useful as agents for lowering intraocular pressure and agents for preventing or treating glaucoma and hyper intraocular pressure
EP0856315B1 (en) Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids
US3577415A (en) 1-substituted-3-substituted phenoxypyrrolidines
RU2004139122A (en) DERIVATIVES OF N-BENZOILUREIDOCORIC ACID, METHOD FOR PRODUCING AND USING THEM
RU2005122615A (en) COMPOUNDS N- (INDOLETHYL) CYCLOAMINE
JP2002529497A5 (en)
JP2665357B2 (en) Pharmaceutical composition for treating heart failure